Targets › CLCN2
1 program from 1 company in 1 trial: 1 Phase 3; Gastroenterology; next expected readout Oct 2027.
Voltage-gated and osmosensitive chloride channel. Forms a homodimeric channel where each subunit has its own ion conduction pathway. (UniProt, P51788)
Open in Phaseline: the race on CLCN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Third Military Medical University | Lubiprostone Chloride channel protein 2 opener | CLCN2 | Phase 3 | Slow Transit Constipation | Oct 2027 |
Slow Transit Constipation (1)
small molecule (1)
Third Military Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.